Physician profile
Terri Pollack
NPI 1104112150
$58,785.16
in general payments reported to CMS, 2019-2025
30 companies · $11K in 2025
The $11K reported for 2025 was more than what 99% of Nurse Practitioner providers received nationally (typical 2025 total: $174).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2021: $19K · 2022: $9,247 · 2023: $11K · 2024: $8,237 · 2025: $11K.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Compensation For Services Other Than Consulting, Including Serving As Faculty Or As A Speaker At A Venue Other Than A Continuing Education Program: $18K · Travel and Lodging: $6,514 · Food and Beverage: $3,533 · Honoraria: $1,450 · Education: $95.00 · Consulting Fee: $38.88.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Compensation For Services Other Than Consulting, Including Serving As Faculty Or As A Speaker At A Venue Other Than A Continuing Education Program | $18,410.00 |
| Travel and Lodging | $6,514.22 |
| Food and Beverage | $3,533.04 |
| Honoraria | $1,450.00 |
| Education | $95.00 |
| Consulting Fee | $38.88 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Incyte Corporation | $31,052.59 | 2021-2025 | Pemazyre, Pemazyre |
| Ipsen Biopharmaceuticals, INC | $17,021.61 | 2021-2025 | Onivyde, Somatuline Depot |
| Tersera Therapeutics LLC | $3,232.79 | 2022 | |
| Exelixis INC. | $2,710.78 | 2025 | Cabometyx |
| Abbvie INC. | $1,407.74 | 2021 | |
| Advanced Accelerator Applications | $812.00 | 2021 | |
| Janssen Biotech, INC. | $318.16 | 2022-2024 | Darzalex, Tecvayli, Balversa |
| Genentech USA, INC. | $276.76 | 2021-2023 | Lunsumio |
| Foundation Medicine, INC. | $218.96 | 2021-2022 | |
| Janssen Scientific Affairs, LLC | $186.63 | 2022-2024 | Erleada, Balversa, Akeega |
| Astrazeneca Pharmaceuticals LP | $148.21 | 2023-2024 | Tagrisso |
| Dendreon Pharmaceuticals LLC | $145.38 | 2023 | Provenge |
| Celgene Corporation | $125.00 | 2021 | |
| Emd Serono, INC. | $125.00 | 2023 | Bavencio |
| E.R. Squibb & Sons, L.L.C. | $122.91 | 2021 |
Show all 30 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Regeneron Healthcare Solutions, INC. | $121.81 | 2024 | Libtayo |
| Genentech, INC. | $112.52 | 2024 | |
| Beigene USA, INC. | $106.73 | 2024 | Tevimbra |
| Seagen INC. | $95.00 | 2024 | |
| Glaxosmithkline, LLC. | $90.73 | 2021 | |
| Astellas Pharma US INC | $77.51 | 2025 | Vyloy |
| Novartis Pharmaceuticals Corporation | $58.36 | 2021-2025 | |
| Cook Medical LLC | $55.02 | 2021-2022 | |
| Caris Mpi, INC. | $45.53 | 2025 | Mi Cancer Seek |
| Pfizer INC. | $23.94 | 2025 | |
| Bayer Healthcare Pharmaceuticals INC. | $22.79 | 2025 | |
| Sun Pharmaceutical Industries INC. | $21.05 | 2024 | |
| Neurocrine Biosciences, INC. | $18.54 | 2021 | |
| Alkermes, INC. | $16.83 | 2021 | |
| Ecs Opco 1 LLC | $14.28 | 2025 | Bioflo, Piccolo Medical, Cook Spectrum |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Terri Pollack listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.